New stent aims to ease dangerous liver complications

NCT ID NCT07390344

Not yet recruiting Disease control Sponsor: W.L.Gore & Associates Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 152 adults with cirrhosis who receive a special stent to treat complications like fluid buildup in the belly or bleeding from enlarged veins. The stent creates a new blood-flow path in the liver. Researchers will monitor how well it works and its safety over 2 years in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm) – a stent that creates a new pathway for blood flow in the liver
What this could lead to: If successful, this could confirm that the device safely controls complications like fluid buildup and bleeding in cirrhosis patients.
What could go wrong: This is an observational registry, not a controlled trial, so results may not prove the device is better than other options. Risks include shunt blockage or need for repeat procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCITES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ascites esophageal varices with bleeding Fibrosis portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCITES PORTAL HYPERTENSION RELATED TO CIRRHOSIS VARICEAL BLEEDING

More trials for these conditions

Other studies related to the condition(s) this trial covers.